I don't see that as a breakthrough.
> Treatment-related adverse events that led to treatment discontinuation occurred in 1.2% of the patients in the daraxonrasib group and in 11.2% of those in the chemotherapy group.
That's a huge reduction in side effects bad enough to stop treatment.